Welcome to our dedicated page for Chemomab Therapeutics SEC filings (Ticker: CMMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Chemomab Therapeutics Ltd. (CMMB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Chemomab files annual reports on Form 20-F and current reports on Form 6-K, which together offer insight into its clinical-stage biotechnology business focused on nebokitug, a monoclonal antibody targeting CCL24 in fibro-inflammatory diseases such as primary sclerosing cholangitis (PSC).
Through its Form 6-K submissions, Chemomab furnishes press releases, unaudited condensed consolidated financial statements, and management’s discussion and analysis for interim periods. These filings detail research and development spending, general and administrative expenses, cash resources and liquidity outlook, as well as narrative updates on the nebokitug development program, including the Phase 2 SPRING trial in PSC and preparations for a planned Phase 3 registration study. Certain 6-Ks also incorporate by reference financial tables, interactive data files and other exhibits into the company’s shelf registration statements and equity compensation plans.
Investors can also review filings that describe capital markets activities, such as at-the-market (ATM) equity offering programs and changes to the ratio of American Depositary Shares (ADSs) to ordinary shares, which effectively function as reverse ADS splits. These documents outline the terms under which Chemomab may sell ADSs, the role of its sales agent, and related legal opinions. Additional 6-Ks report outcomes of shareholder meetings, including director elections, equity awards and auditor appointments.
For those analyzing Chemomab’s governance and regulatory status, the filings page is a central source for information on registration statements on Form F-3 and Form S-8, as well as references to risk factor discussions in the company’s Form 20-F. While detailed clinical protocols and scientific data are often summarized in attached press releases, the SEC filings frame how these developments fit into Chemomab’s overall business, financing strategy and regulatory obligations.
On Stock Titan, these documents are complemented by AI-powered tools that can summarize lengthy filings, highlight key sections related to nebokitug’s PSC program, and help users quickly locate information on topics such as liquidity, share structure changes, or the incorporation by reference of new disclosures into existing registration statements.
Chemomab Therapeutics Ltd. furnished a Form 6-K for August 2025 reporting the inclusion of three exhibits related to its second quarter of 2025. The filing states it includes unaudited condensed consolidated financial statements for the three and six months ended June 30, 2025, the companys Managements Discussion and Analysis of financial condition and results of operations for those periods, and a press release dated August 14, 2025 titled "Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update." The exhibits (99.1, 99.2, 99.3) and interactive financial data files are designated and will be deemed incorporated by reference into specified Form F-3 and Form S-8 registration statements. The report is signed by the Chief Financial Officer, Sigal Fattal.
Chemomab Therapeutics Ltd. has a disclosed beneficial owner, Erik Otto, who holds 1,690,000 American Depositary Shares (ADSs), representing 8.1% of the ADS class. Each ADS represents twenty ordinary shares.
Mr. Otto reports sole voting and sole dispositive power over these ADSs and certifies the holdings were not acquired to change or influence control of the issuer. The ownership percentage is stated based on the issuer's count of outstanding ADSs.
Morgan Stanley and subsidiary file Schedule 13G/A (Amendment 1) for Chemomab Therapeutics (CMMB) covering an ownership change effective 07/31/2025.
- Morgan Stanley reports 13,213,260 ordinary shares/ADS held with shared voting & dispositive power, equal to 3.2 % of Chemomab’s outstanding class.
- Morgan Stanley & Co. LLC reports 9,275,360 shares (shared voting & dispositive power) representing 2.2 % of the class.
- Both filers certify that they have ceased to be beneficial owners of more than 5 % of the issuer’s equity, triggering this amendment.
- Reporting persons are classified as HC/CO (holding company) and BD/CO (broker-dealer) under Item 3.
- No other persons have sole voting or dispositive authority; all powers are shared within the Morgan Stanley reporting units.
- The filing includes a Joint Filing Agreement (Ex. 99.1) and Item 7 subsidiary information (Ex. 99.2).
The amendment signals a reduction of Morgan Stanley’s aggregate position below the 5 % regulatory threshold, though the group still retains a meaningful minority stake.
Schedule 13G filing dated 06/30/2025 shows Morgan Stanley and subsidiary Morgan Stanley & Co. LLC have exceeded the 5 % threshold in Chemomab Therapeutics Ltd. (CMMB).
- Morgan Stanley reports 32,282,680 ordinary shares/ADS, representing 8.4 % of the outstanding class.
- Morgan Stanley & Co. LLC separately holds 28,786,680 shares or 7.5 %.
- Both entities report shared voting and dispositive power; no sole authority is listed.
- Filed under Rule 13d-1(b) as a broker-dealer/holding company, signalling a passive investment rather than a control bid.
- Cover pages classify the parent as “HC, CO” and the subsidiary as “BD, CO.”
- Signatures by authorised signatory Christopher O’Hara are dated 08/07/2025.
The disclosure increases institutional visibility and liquidity for CMMB but contains no operational or strategic changes.
OrbiMed Israel and affiliated entities have filed Amendment No. 5 to Schedule 13D reporting their exit from a significant ownership position in Chemomab Therapeutics Ltd (NASDAQ: CMMB). The filing indicates that following a major transaction, the reporting persons have ceased to be beneficial owners of more than 5% of the company's shares.
Key details of the transaction and current holdings:
- On June 18, 2025, OrbiMed Israel Partners (OIP) sold 1,610,000 American Depositary Shares at $1.10 per ADS
- Current holdings include 131,273 ADSs, 28,817 Warrants, and 809,717 Pre-Funded Warrants
- Total beneficial ownership now represents approximately 4.8% of outstanding shares
The reporting group includes OrbiMed Israel GP Ltd, OrbiMed Israel BioFund GP Limited Partnership, Carl L. Gordon, and Erez Chimovits. The holders maintain registration rights for their remaining securities under a previously established Registration Rights Agreement.
FAQ
What is the current stock price of Chemomab Therapeutics (CMMB)?
What is the market cap of Chemomab Therapeutics (CMMB)?
